nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—ABCB1—Lisinopril—systemic scleroderma	0.0781	0.189	CbGbCtD
Nefazodone—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0707	0.171	CbGbCtD
Nefazodone—ABCB1—Captopril—systemic scleroderma	0.0584	0.141	CbGbCtD
Nefazodone—CYP2D6—Captopril—systemic scleroderma	0.0551	0.133	CbGbCtD
Nefazodone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.046	0.111	CbGbCtD
Nefazodone—ABCB1—Prednisone—systemic scleroderma	0.0368	0.089	CbGbCtD
Nefazodone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0276	0.0667	CbGbCtD
Nefazodone—CYP3A4—Prednisone—systemic scleroderma	0.022	0.0533	CbGbCtD
Nefazodone—ABCB1—Methotrexate—systemic scleroderma	0.0185	0.0447	CbGbCtD
Nefazodone—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000344	0.000587	CcSEcCtD
Nefazodone—Shock—Lisinopril—systemic scleroderma	0.000343	0.000586	CcSEcCtD
Nefazodone—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000342	0.000584	CcSEcCtD
Nefazodone—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000342	0.000583	CcSEcCtD
Nefazodone—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.000341	0.000582	CcSEcCtD
Nefazodone—Tachycardia—Lisinopril—systemic scleroderma	0.000341	0.000581	CcSEcCtD
Nefazodone—Body temperature increased—Azathioprine—systemic scleroderma	0.00034	0.00058	CcSEcCtD
Nefazodone—Abdominal pain—Azathioprine—systemic scleroderma	0.00034	0.00058	CcSEcCtD
Nefazodone—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000338	0.000576	CcSEcCtD
Nefazodone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000337	0.000575	CcSEcCtD
Nefazodone—Diarrhoea—Captopril—systemic scleroderma	0.000337	0.000575	CcSEcCtD
Nefazodone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000337	0.000574	CcSEcCtD
Nefazodone—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000337	0.000574	CcSEcCtD
Nefazodone—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000336	0.000573	CcSEcCtD
Nefazodone—Erectile dysfunction—Prednisone—systemic scleroderma	0.000336	0.000573	CcSEcCtD
Nefazodone—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000335	0.000572	CcSEcCtD
Nefazodone—Feeling abnormal—Leflunomide—systemic scleroderma	0.000335	0.000571	CcSEcCtD
Nefazodone—Mood swings—Methotrexate—systemic scleroderma	0.000334	0.000569	CcSEcCtD
Nefazodone—Nausea—Mometasone—systemic scleroderma	0.000333	0.000568	CcSEcCtD
Nefazodone—Anorexia—Lisinopril—systemic scleroderma	0.000333	0.000567	CcSEcCtD
Nefazodone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000332	0.000566	CcSEcCtD
Nefazodone—Weight increased—Prednisone—systemic scleroderma	0.000332	0.000566	CcSEcCtD
Nefazodone—Ataxia—Methotrexate—systemic scleroderma	0.000331	0.000565	CcSEcCtD
Nefazodone—Pain—Mycophenolic acid—systemic scleroderma	0.000331	0.000565	CcSEcCtD
Nefazodone—Constipation—Mycophenolic acid—systemic scleroderma	0.000331	0.000565	CcSEcCtD
Nefazodone—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000331	0.000565	CcSEcCtD
Nefazodone—Weight decreased—Prednisone—systemic scleroderma	0.00033	0.000562	CcSEcCtD
Nefazodone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000329	0.000562	CcSEcCtD
Nefazodone—Cough—Mycophenolate mofetil—systemic scleroderma	0.000327	0.000558	CcSEcCtD
Nefazodone—Hypotension—Lisinopril—systemic scleroderma	0.000326	0.000556	CcSEcCtD
Nefazodone—Dizziness—Captopril—systemic scleroderma	0.000326	0.000556	CcSEcCtD
Nefazodone—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000325	0.000555	CcSEcCtD
Nefazodone—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000325	0.000554	CcSEcCtD
Nefazodone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000324	0.000552	CcSEcCtD
Nefazodone—Urticaria—Leflunomide—systemic scleroderma	0.000323	0.00055	CcSEcCtD
Nefazodone—Abdominal pain—Leflunomide—systemic scleroderma	0.000321	0.000548	CcSEcCtD
Nefazodone—Body temperature increased—Leflunomide—systemic scleroderma	0.000321	0.000548	CcSEcCtD
Nefazodone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000319	0.000545	CcSEcCtD
Nefazodone—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000319	0.000544	CcSEcCtD
Nefazodone—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000319	0.000544	CcSEcCtD
Nefazodone—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000319	0.000544	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000318	0.000542	CcSEcCtD
Nefazodone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000318	0.000542	CcSEcCtD
Nefazodone—Hypersensitivity—Azathioprine—systemic scleroderma	0.000317	0.00054	CcSEcCtD
Nefazodone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000317	0.00054	CcSEcCtD
Nefazodone—Insomnia—Lisinopril—systemic scleroderma	0.000316	0.000538	CcSEcCtD
Nefazodone—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000315	0.000538	CcSEcCtD
Nefazodone—Paraesthesia—Lisinopril—systemic scleroderma	0.000313	0.000534	CcSEcCtD
Nefazodone—Vomiting—Captopril—systemic scleroderma	0.000313	0.000534	CcSEcCtD
Nefazodone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000312	0.000532	CcSEcCtD
Nefazodone—Dyspnoea—Lisinopril—systemic scleroderma	0.000311	0.000531	CcSEcCtD
Nefazodone—Rash—Captopril—systemic scleroderma	0.000311	0.00053	CcSEcCtD
Nefazodone—Dermatitis—Captopril—systemic scleroderma	0.00031	0.000529	CcSEcCtD
Nefazodone—Somnolence—Lisinopril—systemic scleroderma	0.00031	0.000529	CcSEcCtD
Nefazodone—Headache—Captopril—systemic scleroderma	0.000309	0.000527	CcSEcCtD
Nefazodone—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000308	0.000526	CcSEcCtD
Nefazodone—Dyspepsia—Lisinopril—systemic scleroderma	0.000307	0.000524	CcSEcCtD
Nefazodone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000306	0.000522	CcSEcCtD
Nefazodone—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000306	0.000522	CcSEcCtD
Nefazodone—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000306	0.000522	CcSEcCtD
Nefazodone—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000306	0.000522	CcSEcCtD
Nefazodone—Asthma—Methotrexate—systemic scleroderma	0.000305	0.00052	CcSEcCtD
Nefazodone—Infection—Mycophenolate mofetil—systemic scleroderma	0.000304	0.000518	CcSEcCtD
Nefazodone—Decreased appetite—Lisinopril—systemic scleroderma	0.000303	0.000517	CcSEcCtD
Nefazodone—Shock—Mycophenolate mofetil—systemic scleroderma	0.000301	0.000513	CcSEcCtD
Nefazodone—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000299	0.000511	CcSEcCtD
Nefazodone—Hypersensitivity—Leflunomide—systemic scleroderma	0.000299	0.00051	CcSEcCtD
Nefazodone—Pain—Lisinopril—systemic scleroderma	0.000298	0.000509	CcSEcCtD
Nefazodone—Constipation—Lisinopril—systemic scleroderma	0.000298	0.000509	CcSEcCtD
Nefazodone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000298	0.000509	CcSEcCtD
Nefazodone—Bradycardia—Prednisone—systemic scleroderma	0.000297	0.000507	CcSEcCtD
Nefazodone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000296	0.000504	CcSEcCtD
Nefazodone—Diarrhoea—Azathioprine—systemic scleroderma	0.000294	0.000502	CcSEcCtD
Nefazodone—Haemoglobin—Prednisone—systemic scleroderma	0.000293	0.0005	CcSEcCtD
Nefazodone—Nausea—Captopril—systemic scleroderma	0.000293	0.000499	CcSEcCtD
Nefazodone—Haemorrhage—Prednisone—systemic scleroderma	0.000292	0.000498	CcSEcCtD
Nefazodone—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000292	0.000497	CcSEcCtD
Nefazodone—Asthenia—Leflunomide—systemic scleroderma	0.000291	0.000497	CcSEcCtD
Nefazodone—Hallucination—Prednisone—systemic scleroderma	0.00029	0.000495	CcSEcCtD
Nefazodone—Feeling abnormal—Lisinopril—systemic scleroderma	0.000288	0.000491	CcSEcCtD
Nefazodone—Pruritus—Leflunomide—systemic scleroderma	0.000287	0.00049	CcSEcCtD
Nefazodone—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000286	0.000487	CcSEcCtD
Nefazodone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000285	0.000487	CcSEcCtD
Nefazodone—Dysuria—Methotrexate—systemic scleroderma	0.000285	0.000486	CcSEcCtD
Nefazodone—Dizziness—Azathioprine—systemic scleroderma	0.000284	0.000485	CcSEcCtD
Nefazodone—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000281	0.000478	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000279	0.000475	CcSEcCtD
Nefazodone—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000278	0.000474	CcSEcCtD
Nefazodone—Asthenia—Mycophenolic acid—systemic scleroderma	0.000278	0.000474	CcSEcCtD
Nefazodone—Diarrhoea—Leflunomide—systemic scleroderma	0.000278	0.000474	CcSEcCtD
Nefazodone—Urticaria—Lisinopril—systemic scleroderma	0.000277	0.000473	CcSEcCtD
Nefazodone—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000472	CcSEcCtD
Nefazodone—Abdominal pain—Lisinopril—systemic scleroderma	0.000276	0.000471	CcSEcCtD
Nefazodone—Body temperature increased—Lisinopril—systemic scleroderma	0.000276	0.000471	CcSEcCtD
Nefazodone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000468	CcSEcCtD
Nefazodone—Pruritus—Mycophenolic acid—systemic scleroderma	0.000274	0.000468	CcSEcCtD
Nefazodone—Vomiting—Azathioprine—systemic scleroderma	0.000273	0.000466	CcSEcCtD
Nefazodone—Pneumonia—Methotrexate—systemic scleroderma	0.000273	0.000466	CcSEcCtD
Nefazodone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000465	CcSEcCtD
Nefazodone—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000272	0.000464	CcSEcCtD
Nefazodone—Rash—Azathioprine—systemic scleroderma	0.000271	0.000463	CcSEcCtD
Nefazodone—Dermatitis—Azathioprine—systemic scleroderma	0.000271	0.000462	CcSEcCtD
Nefazodone—Flushing—Prednisone—systemic scleroderma	0.000271	0.000462	CcSEcCtD
Nefazodone—Headache—Azathioprine—systemic scleroderma	0.000269	0.00046	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000269	0.000459	CcSEcCtD
Nefazodone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000269	0.000459	CcSEcCtD
Nefazodone—Dizziness—Leflunomide—systemic scleroderma	0.000269	0.000458	CcSEcCtD
Nefazodone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000266	0.000453	CcSEcCtD
Nefazodone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000265	0.000452	CcSEcCtD
Nefazodone—Stomatitis—Methotrexate—systemic scleroderma	0.000265	0.000452	CcSEcCtD
Nefazodone—Conjunctivitis—Methotrexate—systemic scleroderma	0.000264	0.00045	CcSEcCtD
Nefazodone—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000446	CcSEcCtD
Nefazodone—Pain—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000446	CcSEcCtD
Nefazodone—Sweating—Methotrexate—systemic scleroderma	0.00026	0.000444	CcSEcCtD
Nefazodone—Haematuria—Methotrexate—systemic scleroderma	0.000259	0.000442	CcSEcCtD
Nefazodone—Vomiting—Leflunomide—systemic scleroderma	0.000258	0.00044	CcSEcCtD
Nefazodone—Alopecia—Prednisone—systemic scleroderma	0.000258	0.00044	CcSEcCtD
Nefazodone—Hypersensitivity—Lisinopril—systemic scleroderma	0.000257	0.000439	CcSEcCtD
Nefazodone—Dizziness—Mycophenolic acid—systemic scleroderma	0.000256	0.000437	CcSEcCtD
Nefazodone—Epistaxis—Methotrexate—systemic scleroderma	0.000256	0.000437	CcSEcCtD
Nefazodone—Rash—Leflunomide—systemic scleroderma	0.000256	0.000437	CcSEcCtD
Nefazodone—Dermatitis—Leflunomide—systemic scleroderma	0.000256	0.000436	CcSEcCtD
Nefazodone—Nausea—Azathioprine—systemic scleroderma	0.000256	0.000436	CcSEcCtD
Nefazodone—Headache—Leflunomide—systemic scleroderma	0.000254	0.000434	CcSEcCtD
Nefazodone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000252	0.00043	CcSEcCtD
Nefazodone—Asthenia—Lisinopril—systemic scleroderma	0.00025	0.000427	CcSEcCtD
Nefazodone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00025	0.000426	CcSEcCtD
Nefazodone—Pruritus—Lisinopril—systemic scleroderma	0.000247	0.000421	CcSEcCtD
Nefazodone—Vomiting—Mycophenolic acid—systemic scleroderma	0.000246	0.00042	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—systemic scleroderma	0.000245	0.000418	CcSEcCtD
Nefazodone—Rash—Mycophenolic acid—systemic scleroderma	0.000244	0.000417	CcSEcCtD
Nefazodone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000244	0.000416	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—systemic scleroderma	0.000244	0.000416	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—systemic scleroderma	0.000244	0.000416	CcSEcCtD
Nefazodone—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000243	0.000414	CcSEcCtD
Nefazodone—Headache—Mycophenolic acid—systemic scleroderma	0.000243	0.000414	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—systemic scleroderma	0.000242	0.000413	CcSEcCtD
Nefazodone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000412	CcSEcCtD
Nefazodone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000412	CcSEcCtD
Nefazodone—Nausea—Leflunomide—systemic scleroderma	0.000241	0.000411	CcSEcCtD
Nefazodone—Vision blurred—Prednisone—systemic scleroderma	0.000239	0.000408	CcSEcCtD
Nefazodone—Diarrhoea—Lisinopril—systemic scleroderma	0.000239	0.000407	CcSEcCtD
Nefazodone—Ill-defined disorder—Prednisone—systemic scleroderma	0.000236	0.000402	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—systemic scleroderma	0.000235	0.000401	CcSEcCtD
Nefazodone—Anaemia—Prednisone—systemic scleroderma	0.000235	0.0004	CcSEcCtD
Nefazodone—Agitation—Prednisone—systemic scleroderma	0.000233	0.000398	CcSEcCtD
Nefazodone—Angioedema—Prednisone—systemic scleroderma	0.000232	0.000396	CcSEcCtD
Nefazodone—Dizziness—Lisinopril—systemic scleroderma	0.000231	0.000394	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—systemic scleroderma	0.000231	0.000393	CcSEcCtD
Nefazodone—Nausea—Mycophenolic acid—systemic scleroderma	0.00023	0.000393	CcSEcCtD
Nefazodone—Malaise—Prednisone—systemic scleroderma	0.000229	0.000391	CcSEcCtD
Nefazodone—Vertigo—Prednisone—systemic scleroderma	0.000228	0.000389	CcSEcCtD
Nefazodone—Syncope—Prednisone—systemic scleroderma	0.000228	0.000388	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—systemic scleroderma	0.000227	0.000388	CcSEcCtD
Nefazodone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000225	0.000384	CcSEcCtD
Nefazodone—Loss of consciousness—Prednisone—systemic scleroderma	0.000223	0.000381	CcSEcCtD
Nefazodone—Vomiting—Lisinopril—systemic scleroderma	0.000222	0.000378	CcSEcCtD
Nefazodone—Rash—Lisinopril—systemic scleroderma	0.00022	0.000375	CcSEcCtD
Nefazodone—Convulsion—Prednisone—systemic scleroderma	0.00022	0.000375	CcSEcCtD
Nefazodone—Dermatitis—Lisinopril—systemic scleroderma	0.00022	0.000375	CcSEcCtD
Nefazodone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000219	0.000374	CcSEcCtD
Nefazodone—Hypertension—Prednisone—systemic scleroderma	0.000219	0.000374	CcSEcCtD
Nefazodone—Chills—Methotrexate—systemic scleroderma	0.000219	0.000373	CcSEcCtD
Nefazodone—Headache—Lisinopril—systemic scleroderma	0.000219	0.000373	CcSEcCtD
Nefazodone—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000369	CcSEcCtD
Nefazodone—Myalgia—Prednisone—systemic scleroderma	0.000216	0.000369	CcSEcCtD
Nefazodone—Arthralgia—Prednisone—systemic scleroderma	0.000216	0.000369	CcSEcCtD
Nefazodone—Anxiety—Prednisone—systemic scleroderma	0.000216	0.000367	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—systemic scleroderma	0.000215	0.000367	CcSEcCtD
Nefazodone—Discomfort—Prednisone—systemic scleroderma	0.000214	0.000364	CcSEcCtD
Nefazodone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000209	0.000357	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—systemic scleroderma	0.000208	0.000354	CcSEcCtD
Nefazodone—Nausea—Lisinopril—systemic scleroderma	0.000207	0.000354	CcSEcCtD
Nefazodone—Anaphylactic shock—Prednisone—systemic scleroderma	0.000207	0.000354	CcSEcCtD
Nefazodone—Oedema—Prednisone—systemic scleroderma	0.000207	0.000354	CcSEcCtD
Nefazodone—Infection—Prednisone—systemic scleroderma	0.000206	0.000351	CcSEcCtD
Nefazodone—Back pain—Methotrexate—systemic scleroderma	0.000205	0.00035	CcSEcCtD
Nefazodone—Shock—Prednisone—systemic scleroderma	0.000204	0.000348	CcSEcCtD
Nefazodone—Tachycardia—Prednisone—systemic scleroderma	0.000202	0.000345	CcSEcCtD
Nefazodone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000202	0.000345	CcSEcCtD
Nefazodone—Hyperhidrosis—Prednisone—systemic scleroderma	0.0002	0.000342	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—systemic scleroderma	0.0002	0.000341	CcSEcCtD
Nefazodone—Anorexia—Prednisone—systemic scleroderma	0.000198	0.000337	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000197	0.000336	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—systemic scleroderma	0.000196	0.000335	CcSEcCtD
Nefazodone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000332	CcSEcCtD
Nefazodone—Rash—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000329	CcSEcCtD
Nefazodone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000193	0.000329	CcSEcCtD
Nefazodone—Headache—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000327	CcSEcCtD
Nefazodone—Malaise—Methotrexate—systemic scleroderma	0.000191	0.000326	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—systemic scleroderma	0.000191	0.000325	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—systemic scleroderma	0.00019	0.000324	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000189	0.000322	CcSEcCtD
Nefazodone—Insomnia—Prednisone—systemic scleroderma	0.000187	0.00032	CcSEcCtD
Nefazodone—Paraesthesia—Prednisone—systemic scleroderma	0.000186	0.000317	CcSEcCtD
Nefazodone—Cough—Methotrexate—systemic scleroderma	0.000185	0.000316	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—systemic scleroderma	0.000184	0.000314	CcSEcCtD
Nefazodone—Dyspepsia—Prednisone—systemic scleroderma	0.000182	0.000311	CcSEcCtD
Nefazodone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000182	0.00031	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—systemic scleroderma	0.000181	0.000308	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—systemic scleroderma	0.000181	0.000308	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—systemic scleroderma	0.000181	0.000308	CcSEcCtD
Nefazodone—Decreased appetite—Prednisone—systemic scleroderma	0.00018	0.000307	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—systemic scleroderma	0.000179	0.000304	CcSEcCtD
Nefazodone—Constipation—Prednisone—systemic scleroderma	0.000177	0.000302	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—systemic scleroderma	0.000175	0.000298	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000173	0.000295	CcSEcCtD
Nefazodone—Infection—Methotrexate—systemic scleroderma	0.000172	0.000294	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisone—systemic scleroderma	0.000171	0.000291	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—systemic scleroderma	0.00017	0.000289	CcSEcCtD
Nefazodone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.00017	0.000289	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000167	0.000286	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—systemic scleroderma	0.000165	0.000282	CcSEcCtD
Nefazodone—Urticaria—Prednisone—systemic scleroderma	0.000165	0.000281	CcSEcCtD
Nefazodone—Abdominal pain—Prednisone—systemic scleroderma	0.000164	0.000279	CcSEcCtD
Nefazodone—Body temperature increased—Prednisone—systemic scleroderma	0.000164	0.000279	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—systemic scleroderma	0.000162	0.000276	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000158	0.000269	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—systemic scleroderma	0.000157	0.000267	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—systemic scleroderma	0.000156	0.000265	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—systemic scleroderma	0.000154	0.000263	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—systemic scleroderma	0.000154	0.000263	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisone—systemic scleroderma	0.000153	0.00026	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—systemic scleroderma	0.000153	0.00026	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—systemic scleroderma	0.000151	0.000257	CcSEcCtD
Nefazodone—Asthenia—Prednisone—systemic scleroderma	0.000149	0.000254	CcSEcCtD
Nefazodone—Pain—Methotrexate—systemic scleroderma	0.000148	0.000253	CcSEcCtD
Nefazodone—Pruritus—Prednisone—systemic scleroderma	0.000147	0.00025	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—systemic scleroderma	0.000143	0.000243	CcSEcCtD
Nefazodone—Diarrhoea—Prednisone—systemic scleroderma	0.000142	0.000242	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000142	0.000242	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—systemic scleroderma	0.000138	0.000235	CcSEcCtD
Nefazodone—Dizziness—Prednisone—systemic scleroderma	0.000137	0.000234	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—systemic scleroderma	0.000137	0.000234	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—systemic scleroderma	0.000137	0.000234	CcSEcCtD
Nefazodone—Vomiting—Prednisone—systemic scleroderma	0.000132	0.000225	CcSEcCtD
Nefazodone—Rash—Prednisone—systemic scleroderma	0.000131	0.000223	CcSEcCtD
Nefazodone—Dermatitis—Prednisone—systemic scleroderma	0.000131	0.000223	CcSEcCtD
Nefazodone—Headache—Prednisone—systemic scleroderma	0.00013	0.000221	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—systemic scleroderma	0.000128	0.000218	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—systemic scleroderma	0.000124	0.000212	CcSEcCtD
Nefazodone—Nausea—Prednisone—systemic scleroderma	0.000123	0.00021	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—systemic scleroderma	0.000123	0.000209	CcSEcCtD
Nefazodone—HTR2A—myenteric nerve plexus—systemic scleroderma	0.00012	0.242	CbGeAlD
Nefazodone—Diarrhoea—Methotrexate—systemic scleroderma	0.000119	0.000202	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—systemic scleroderma	0.000115	0.000195	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—systemic scleroderma	0.00011	0.000188	CcSEcCtD
Nefazodone—Rash—Methotrexate—systemic scleroderma	0.000109	0.000186	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—systemic scleroderma	0.000109	0.000186	CcSEcCtD
Nefazodone—Headache—Methotrexate—systemic scleroderma	0.000109	0.000185	CcSEcCtD
Nefazodone—Nausea—Methotrexate—systemic scleroderma	0.000103	0.000175	CcSEcCtD
Nefazodone—HTR2A—pulmonary artery—systemic scleroderma	8.46e-05	0.172	CbGeAlD
Nefazodone—HTR2A—artery—systemic scleroderma	3.14e-05	0.0636	CbGeAlD
Nefazodone—HTR2A—endothelium—systemic scleroderma	2.65e-05	0.0537	CbGeAlD
Nefazodone—HTR2A—blood vessel—systemic scleroderma	2.44e-05	0.0496	CbGeAlD
Nefazodone—SLC6A4—digestive system—systemic scleroderma	1.71e-05	0.0347	CbGeAlD
Nefazodone—ABCB1—blood vessel—systemic scleroderma	1.6e-05	0.0325	CbGeAlD
Nefazodone—SLC6A3—lung—systemic scleroderma	1.56e-05	0.0316	CbGeAlD
Nefazodone—ADRA2A—connective tissue—systemic scleroderma	1.47e-05	0.0299	CbGeAlD
Nefazodone—SLC6A4—lung—systemic scleroderma	1.43e-05	0.029	CbGeAlD
Nefazodone—SLC6A2—lung—systemic scleroderma	1.26e-05	0.0255	CbGeAlD
Nefazodone—HTR2A—connective tissue—systemic scleroderma	1.25e-05	0.0254	CbGeAlD
Nefazodone—HTR2A—smooth muscle tissue—systemic scleroderma	1.15e-05	0.0232	CbGeAlD
Nefazodone—CYP3A5—digestive system—systemic scleroderma	1.12e-05	0.0226	CbGeAlD
Nefazodone—ADRA2A—tendon—systemic scleroderma	1.01e-05	0.0205	CbGeAlD
Nefazodone—CYP3A5—lung—systemic scleroderma	9.32e-06	0.0189	CbGeAlD
Nefazodone—HTR2A—digestive system—systemic scleroderma	9.05e-06	0.0184	CbGeAlD
Nefazodone—ADRA2A—lung—systemic scleroderma	8.89e-06	0.018	CbGeAlD
Nefazodone—HTR2A—tendon—systemic scleroderma	8.61e-06	0.0175	CbGeAlD
Nefazodone—CYP3A4—digestive system—systemic scleroderma	8.38e-06	0.017	CbGeAlD
Nefazodone—CYP2D6—digestive system—systemic scleroderma	8.25e-06	0.0167	CbGeAlD
Nefazodone—HTR2A—lung—systemic scleroderma	7.56e-06	0.0153	CbGeAlD
Nefazodone—ABCB1—digestive system—systemic scleroderma	5.93e-06	0.012	CbGeAlD
Nefazodone—ABCB1—lung—systemic scleroderma	4.95e-06	0.01	CbGeAlD
